Recruiting

Observational Study

Sponsor:

University of Geneva, Switzerland

Code:

NCT01607788

Conditions

Hepatocellular Carcinoma

Evidence of Liver Transplantation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The investigators propose a prospective, web-based database (developed within the framework of Quickbase, Intuit) which will allow an evaluation of the data for patients with a liver tumour who receive a liver transplant. Each site will continue to transplant according to their own criteria for inclusion on the waiting list. Each center will be responsible to enter a short list of data points at time of listing, transplant, and at 1 and 2 years post transplant. Data will be gathered prospectively through a web-based anaonymized database, and outcomes analyzed yearly X5 for tumour recurrence and patient survival.

Conditions

Hepatocellular Carcinoma

Evidence of Liver Transplantation

Study ID

NCT01607788

Start date

Nov, 2009

Status verified date

May, 2012

Completion date

Dec, 2017

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • patients with hepatocellular carcinoma listed for liver transplantation

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Post-transplant survival [ Time Frame: 24 months post-transplant ]

Central Contacts and Locations

Central contacts

Norman Kneteman, MD

kneteman@ualberta.ca

Locations

University of Alberta

Recruiting

Edmonton, Canada

Contacts

Norman Kneteman, MD

kneteman@ualberta.ca

Principal Investigator:

Norman Kneteman, MD

More Information

Sponsor

University of Geneva, Switzerland

Last update posted

May 30, 2012

Last verified

May, 2012

Keywords

  • Selection criteria
  • Liver transplantation
  • Hepatocellular carcinoma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Geneva, Switzerland on 2012-05-30.